Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: SGLT2 inhibitors


SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes

November 5th 2020

This article summarises the evidence regarding the use of SGLT2i medicines in slowing the progression of DKD and examines the possible mechanisms underpinning the renoprotective effects of these agents (Diabetes Therapy)

Categories: Nephropathy, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Nephropathy
Tags: SGLT2 inhibitors, Type 2 Diabetes

Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience

October 29th 2020

Efficacy, renal safety and tolerability of SGLT2i were similar in people >70 compared to 65–70 years of age, suggesting that a wider use should not be worried even in the elderly. However, some caution must be paid to the occurrence of persistent eGFR decline and orthostatic hypotension, especially in patients >70 years old (Primary Care Diabetes)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 2 Diabetes

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

October 25th 2020

Central to our manifesto is a shift from linear treatment algorithms based on HbA1c target setting to parallel, independent considerations of atherosclerotic cardiovascular disease, heart failure and renal risks, in accordance with newly updated guidelines (Cardiovascular Diabetology)

Categories: News, Treatment
Tags: GLP-1 RA, SGLT2 inhibitors, Type 2 Diabetes

Categories: Treatment
Tags: GLP-1 RA, SGLT2 inhibitors, Type 2 Diabetes

Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials

October 23rd 2020

This review suggests that there is a significantly lower risk of incident AF for individuals on SGLT2 inhibitors versus placebo (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, News
Tags: SGLT2 inhibitors

Categories: Cardiovascular
Tags: SGLT2 inhibitors

SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes

October 12th 2020

Treatment with SGLT2 inhibitors results in clear and consistent reductions in cardiovascular, kidney and mortality outcomes regardless of whether patients are receiving or not receiving metformin (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: SGLT2 inhibitors

Categories: Medication
Tags: SGLT2 inhibitors

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?

October 11th 2020

SGLT-2 inhibitors are the latest class of therapies to demonstrate important clinical benefits among patients with HFrEF, and their pharmacological properties favor ease of use and integration in multi-drug disease-modifying regimens (Current Cardiology Reports)

Categories: Cardiovascular, News
Tags: SGLT2 inhibitors

Categories: Cardiovascular
Tags: SGLT2 inhibitors

Effects of SGL2 inhibitors on liver parameters and steatosis: a meta‐analysis of randomized clinical trials

October 4th 2020

Treatment with SGLT2 inhibitors improves liver structure and function in patients with type 2 diabetes. This meta‐analysis suggests that SGLT2 inhibitors are a promising pharmacological approach to NAFLD (Diabetes/Metabolism Research and Reviews)

Categories: Medication, News
Tags: NAFLD, SGLT2 inhibitors

Categories: Medication
Tags: NAFLD, SGLT2 inhibitors

Potential Unrealized Mortality Benefit of GLP‐1 Receptor Agonists and SGLT2 Inhibitors

September 10th 2020

This analysis indicates unrealized opportunities to reduce mortality in selected Veterans with T2D and CAD via increased use of GLP‐1RA and SGLT2i (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: GLP‐1RA, mortality, SGLT2 inhibitors

Categories: Medication
Tags: GLP‐1RA, mortality, SGLT2 inhibitors

Lower Cardiorenal Risk with Sodium‐Glucose Cotransporter‐2 Inhibitors versus Dipeptidyl Peptidase‐4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases

September 8th 2020

In this multinational observational study, SGLT2i was associated with lower risk of heart failure and chronic kidney disease versus DPP4i in T2D patients otherwise free from both cardiovascular and renal disease (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: Cardiorenal, DPP-4 inhibitors, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: Cardiorenal, DPP-4 inhibitors, SGLT2 inhibitors, Type 2 Diabetes

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care

September 3rd 2020

Based on the current understandings and lessons learned from the most recent studies, we discussed the importance of future research on the safety and efficacy of SGLT2 inhibitor in clinical situations of HF other than those examined in previous cardiovascular outcome trials (Cardiovascular Diabetology)

Categories: Medication, News
Tags: SGLT2 inhibitors

Categories: Medication
Tags: SGLT2 inhibitors

Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis

September 2nd 2020

These data indicate that SGLT-2is is more beneficial to MACE and all-cause mortality in T2DM patients than DPP-4is (Primary Care Diabetes)

Categories: Medication, News
Tags: DPP4i, GLP1 receptor agonist, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: DPP4i, GLP1 receptor agonist, SGLT2 inhibitors, Type 2 Diabetes

SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials

August 28th 2020

SGLT2 inhibitors may confer a specific AF/AFL-reduction benefit in the susceptible type 2 diabetes population, regardless of age, body weight, HbA1c, and systolic blood pressure at baseline (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: AF, SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular
Tags: AF, SGLT2 inhibitors, Type 2 Diabetes

Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function

August 18th 2020

Preclinical studies indicate that SGLT-2 inhibitors attenuate vascular dysfunction in preclinical models via a combination of mechanisms that appear to act independently of glucose-lowering benefits (Diabetes Therapy)

Categories: Medication, News
Tags: endothelial, endothelial function, SGLT2 inhibitors

Categories: Medication
Tags: endothelial, endothelial function, SGLT2 inhibitors

A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress

August 12th 2020

There is heterogeneous, yet consistent data supporting the beneficial effects of SLGT2is on inflammatory and oxidative stress. Change in serum CRP appears to be independent of change in HbA1c (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: oxidative stress, SGLT2 inhibitors

Categories: Medication
Tags: oxidative stress, SGLT2 inhibitors

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis

July 29th 2020

SGLT-2 inhibitors were associated with an almost 3-fold increased risk for DKA, with molecule-specific analyses suggesting a class effect (Annals of Internal Medicine)

Categories: Medication, News
Tags: DKA, SGLT2 inhibitors

Categories: Medication
Tags: DKA, SGLT2 inhibitors

Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes

July 15th 2020

The glucose-lowering efficacy of SGLT-2i, and to a lesser extent DPP-4i, was greater in studies of predominantly Asian ethnicity compared with studies of predominantly white ethnicity. There was no difference seen by ethnicity for GLP-1RA (Diabetes Care)

Categories: Medication, News
Tags: DPP-4i, GLP-1RA, SGLT2 inhibitors

Categories: Medication
Tags: DPP-4i, GLP-1RA, SGLT2 inhibitors

SGLT2i: beyond the glucose-lowering effect

June 28th 2020

The information presented provides a theoretical basis for the clinical prevention and treatment of diabetes and its complications and for the development of new glucose-lowering drugs (Cardiovascular Diabetology)

Categories: Medication, News
Tags: SGLT2 inhibitors

Categories: Medication
Tags: SGLT2 inhibitors

Diabetes medications with cardiovascular protection as we enter a new decade

June 10th 2020

Can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives? (ABCD)

Categories: Medication, News
Tags: GLP1, metformin, pioglitazone, SGLT2 inhibitors

Categories: Medication
Tags: GLP1, metformin, pioglitazone, SGLT2 inhibitors

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients

May 31st 2020

Use of SGLT2i improved cardiac function in diabetic patients, regardless of the presence of HF. The improvements were more prominent in HF patients, especially in those with HFrEF. These improvements in cardiac function would contribute to the clinical benefit of SGLT2i (Cardiovascular Diabetology)

Categories: Medication, News
Tags: heart failure, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: heart failure, SGLT2 inhibitors, Type 2 Diabetes

Comparative effectiveness of dapagliflozin vs DPP ‐4 inhibitors on a composite endpoint of HbA1c , body weight, and blood pressure reduction in the real world

May 27th 2020

T2D patients initiating the SGLT2i dapagliflozin had a greater probability of attaining a composite endpoint of clinically relevant reductions in HbA1c, body weight and SBP, compared to similar patients initiating a DPP‐4i in the same period and healthcare setting (Diabetes/Metabolism Research and Reviews)

Categories: Medication, News
Tags: dapagliflozin, DPP‐4i, HbA1c, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: dapagliflozin, DPP‐4i, HbA1c, SGLT2 inhibitors, Type 2 Diabetes
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesNovo NordiskSanofi DiabetesAstraZeneca

Silver Sponsors

About Ascensia Diabetes CareAmgenWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes USA Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership